Exact Mass: 474.0943

Exact Mass Matches: 474.0943

Found 30 metabolites which its exact mass value is equals to given mass value 474.0943, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid

C23H23ClN2O5S (474.1016)

3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid

3-[({4-[4-({[1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulphanyl]propanoic acid

C23H23ClN2O5S (474.1016)

Rilmazafone

2-Amino-N-({1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-3-(dimethylcarbamoyl)-1H-1,2,4-triazol-5-yl}methyl)ethanimidate

C21H20Cl2N6O3 (474.0974)

Ki16425

3-[[[4-[4-[[[1-(2-chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazoly]phenyl]methyl]thio]-propanoic acid

C23H23ClN2O5S (474.1016)

CDP-N-dimethylethanolamine

C13H24N4O11P2 (474.0917)

HEXYLTRIPHENYLPHOSPHONIUM IODIDE

C24H28IP (474.0973)

halopredone

C21H25BrF2O5 (474.0853)

Rilmazafone

C21H20Cl2N6O3 (474.0974)

D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic

Benzeneacetic acid, 4-chloro-a-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]benzo[b]thien-6-yl]oxy]-, methyl ester

C23H23ClN2O5S (474.1016)

METHYL3,4-DI[[(4-METHYLPHENYL)SULFONYL]AMINO]BENZOATE

C22H22N2O6S2 (474.0919)

6-Chloro-2-oxo-4-methylchromen-7-yl 4-O-beta-D-xylopyranosyl-beta-D-xylopyranoside

C20H23ClO11 (474.0929)

N-(4-CHLORO-2-METHYLPHENYL)-2-(N-(3,4-DIMETHOXYPHENYL)PHENYLSULFONAMIDO)ACETAMIDE

C23H23ClN2O5S (474.1016)

BIS(2-(4-AZIDOSALICYLAMIDO)ETHYL) DISULF

C18H18N8O4S2 (474.0892)

CDP-N,N-dimethylethanolamine

C13H24N4O11P2 (474.0917)

[4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone

C22H20Cl2N4O4 (474.0862)

5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide

C22H20ClFN4O3S (474.0929)

CID 157010213

C13H24N4O11P2+ (474.0917)

3-[({4-[4-({[(1S)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid

C23H23ClN2O5S (474.1016)

3-[({4-[4-({[(1R)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid

C23H23ClN2O5S (474.1016)

1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperidine-3-carboxamide

C21H22N4O5S2 (474.1032)

GluN2B-NMDAR antagonist-1

C26H23BrN2O2 (474.0943)

GluN2B-NMDAR antagonist-1 is an orally active GluN2B-NMDAR antagonist. GluN2B-NMDAR antagonist-1 has neuroprotective activity. GluN2B-NMDAR antagonist-1 can be used for research of ischemic injury[1].

5,13,17,19-tetrahydroxy-15,22-dioxo-7-(2-oxopropyl)pentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁶,²¹]docosa-1(14),2,4(9),5,7,12,16,18,20-nonaene-6-carboxylic acid

C26H18O9 (474.0951)

(1s,14r,24s)-3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione

C26H18O9 (474.0951)

3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione

C26H18O9 (474.0951)

16-(2,4-dihydroxy-6-methylbenzoyl)-4,10-dihydroxy-6-methoxy-12-methyl-14-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,9(17),10,12-heptaene-8,15-dione

C26H18O9 (474.0951)

(1s,14r,24r)-3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione

C26H18O9 (474.0951)